Press Releases

1. Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer. March 15, 2023
2. Resolve Biosciences Expands Meridian Molecular Cartography™ Service Program for Virtually Any Species or Tissue Type at AGBT 2023. February 6, 2023
3. Resolve Biosciences to Showcase the Versatility and Data Quality of Molecular Cartography at the 30th Annual Plant and Animal Genome Conference. January 9, 2023
4. Announcing the Winners of The Scientist’s Top 10 Innovations of 2022. December 12, 2022
5. Resolve Biosciences Appoints Chief Commercial Officer to Drive Worldwide Adoption of Molecular Cartography™ Workflow. October 25, 2022
6. Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow. October 24, 2022
7. Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow. June 7, 2022
8. Resolve Biosciences to Showcase Agrigenomic Applications for Molecular Cartography™ Platform at Advances in Genome Biology and Technology Agriculture Meeting. April 4, 2022
9. Resolve Biosciences Joins EMBL’s Corporate Partnership Programme. Dec. 9, 2021
10. Resolve Biosciences Appoints Oliver Dick as Chief Operating Officer. Dec. 01, 2021
11. Announcing the Winners of The Scientist’s Top 10 Innovations of 2021. Dec. 01, 2021
12. Resolve Biosciences Strengthens Leadership Team with Appointment of Frank Zhong as Chief Technology Officer. Nov. 2, 2021
13. Resolve Biosciences Appoints Erik Wiberg as Chief Financial Officer. Sept. 13, 2021
14. Resolve Biosciences and ZEISS Announce Co-Development Collaboration to Enhance Highest-Resolution View of Subcellular Spatial Biology. Aug. 3, 2021
15. Resolve Biosciences Launches Commercial Molecular Cartography™ Services to Provide Scientists with Highest-Resolution View of Subcellular Gene Expression. June 2, 2021
16. Resolve Biosciences Announces Initial Results from Early Access Collaborations with Scientists Leading the Next Generation of Subcellular Spatial Analysis. Feb. 22, 2021
17. Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis. Dec. 10, 2020

Resolve Biosciences Announces Appointment of John Stark as Chief Executive Officer

Life sciences tools veteran brings decades of experience leading successful teams, commercializing industry-defining technology platforms, and scaling global organizations.

MONHEIM AM RHEIN, Germany – March 15, 2023 – Resolve Biosciences, a company pioneering Molecular Cartography™ technology, announced today that it has appointed John Stark as Chief Executive Officer. As part of this transition, Resolve Biosciences’ previous CEO, Jason Gammack, will be leaving the company.

Mr. Stark brings more than 20 years of experience commercializing early-stage technologies, scaling organizations, and navigating capital markets for some of the most innovative life sciences companies. Most recently, Mr. Stark was Chief Executive Officer of Quantum-Si (NASDAQ: QSI), a next-generation, single-molecule protein sequencing platform company. Prior to that, he served as CEO of Celsee, a novel single-cell genomics platform company that was acquired by Bio-Rad (NYSE: BIO) in 2020. Earlier in his career, Mr. Stark held senior leadership positions at Life Technologies (acquired by Thermo Fisher Scientific, NYSE:TMO), Pacific Biosciences (NASDAQ: PACB), and Affymetrix (acquired by Thermo Fisher Scientific).

“The Board is excited to welcome John to Resolve Biosciences to lead our next chapter of growth and success,” said Peer M. Schatz, co-founder and Chairman of the Board. “John brings an impressive track record of execution, operational excellence, and successful team building to drive innovation. Throughout his career, John has consistently delivered high-growth results for numerous industry-defining platforms. We look forward to working with him on our quest to shape the future of spatial biology and realize the massive opportunities and vast applications in science and medicine.”

Mr. Schatz added, “We deeply appreciate Jason Gammack for his contributions and leadership of the company as former CEO, including shepherding the company through the COVID-19 pandemic and initial launch of our commercial platform and service offering.”

“I am honored to join Resolve Biosciences as its next Chief Executive Officer,” said Mr. Stark. “It is rare to find an opportunity like this to lead a growing company with a transformative technology and a brilliant and passionate team. I’m looking forward to empowering our global partners and customers with the ability to realize the full potential of our Molecular Cartography technology. We are dedicated to delivering best-in-class products that will enable the understanding of the molecular causes of disease and associated immune response.”

---

Resolve Biosciences Expands Meridian Molecular Cartography™ Service Program for Virtually Any Species or Tissue Type at AGBT 2023

Customers can now access company’s groundbreaking technology without an instrument purchase to quickly generate the industry’s highest-quality 3D spatial transcriptomics data

MONHEIM AM RHEIN, Germany – February 6, 2023 – Resolve Biosciences, the pioneer in Molecular Cartography™ technology, today announced the expansion of its end-to-end Meridian service offering for spatial transcriptomics data. Scientists who do not have access to their own system can now submit a broad range of samples, including fresh-frozen, fixed, or FFPE tissue, and receive highly multiplexed in situ gene expression data from Resolve Biosciences’ team of technical experts. The program is designed to get results to customers faster, enabling them to glean new insights and make new discoveries as quickly as possible. The company will unveil its expanded Meridian service program and discuss the latest advances in Molecular Cartography technology at this week’s Advances in Genome Biology and Technology (AGBT) General Meeting.

“The quality of the data and amount of information generated from the Meridian Molecular Cartography service was very impressive,” said Satdarshan (Paul) S. Monga, MD, Endowed Chair for Experimental Pathology at the University of Pittsburgh Medical Center and Director of Pittsburgh Liver Research Center. “We were able to clearly visualize subcellular gene expression activity with unparalleled sensitivity and specificity.”

“From day one, the team at Resolve Biosciences has been laser-focused on improving data quality and making our Molecular Cartography platform the industry’s most accessible and adaptable spatial biology system,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “With our expanded Meridian service offering, more customers can now apply the full power of our Molecular Cartography system to virtually any species or tissue type, including FFPE. We have seen customers go from sample submission to manuscript in just a few weeks, demonstrating the remarkable acceleration of science our service makes possible.”

Technology Accessibility

Researchers around the world can take advantage of the Meridian service offering to gain access to Resolve Biosciences’ proprietary, highly multiplexed, single-molecule fluorescence in situ hybridization technology. From custom panel design to data analysis, the complete spatial transcriptomics workflow can be optimized by the company’s scientific team to meet the specific requirements for each project. Unlike other spatial analysis techniques, the system provides the required 3D accuracy, sensitivity, and specificity to elucidate a cell’s complex transcriptional landscape. The deep contextual data sets illuminate molecular interactions while preserving sample tissue for future analysis. For more information on the Meridian service program, please visit www.resolvebiosciences.com/meridian-services.

Workflow Flexibility

Resolve Biosciences’ pioneering Molecular Cartography technology was designed for the multiplexing needs of most scientists in basic, translational, and clinical research. Over the past two years, the technology has revealed numerous insights in neurology, oncology, developmental biology, and many other important biological research areas. The technology has now been used to process more than 50 tissue types and has already been cited in more than 15 manuscripts and peer-reviewed scientific publications.

Resolve will begin offering FFPE tissue capabilities as part of its Meridian service program and will add the feature to its commercial Molecular Cartography systems later this year. In the future, the company will continue to enhance the modular platform by incorporating the interrogation of DNA, protein, and metabolomic data layers.

AGBT 2023 General Meeting

Resolve Biosciences is a proud bronze sponsor of the AGBT General Meeting, taking place this week in Hollywood, Fla. The company will share insights into critical components of spatial biology data quality and showcase the latest scientific advances made possible by its Molecular Cartography workflow during its workshop and throughout the meeting in Suite #213. For more information on the company’s AGBT activities, please visit www.resolvebiosciences.com/agbt-2023.

---

Resolve Biosciences to Showcase the Versatility and Data Quality of Molecular Cartography at the 30th Annual Plant and Animal Genome Conference

Company launches grant program to empower scientists with access to the only subcellular, in situ analysis platform optimized for spatial agrigenomics

MONHEIM AM RHEIN, Germany – January 9, 2023 – Resolve Biosciences, the pioneer in Molecular Cartography™ technology, today announced a lineup of customer presentations at the 30th annual Plant and Animal Genome (PAG) Conference in San Diego on January 13-18, 2022. Meeting attendees will be able to learn more about the technology in booth #431 and hear leading international scientists present data on how they are applying the power of the Molecular Cartography spatial transcriptomics technology to advance agricultural and animal genomics research.

“From the start, the Resolve Biosciences team saw the need to bring the many advantages of Molecular Cartography spatial transcriptomics technology to the plant and animal genome research community, which is underrepresented by current genomic tools,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “With the flexibility to support a broad range of species and tissue types, our Molecular Cartography platform is the most adaptable and applicable spatial biology system, and we are committed to empowering scientists with the ability to gain never-before-seen biological insights that can help improve, protect, and enhance sustainable food production.”

Resolve Biosciences Customer Workshop

Monday, Jan. 16th at 4:00 pm PT in Town & Country Conference Center; Pacific D

• Using Spatial Transcriptomics to Construct a Single-cell Atlas of Rice
  Philip Benfey, PhD, Duke University
• Transcriptional Gradients in the Maize Shoot Apex
  Hilde Nelissen, PhD, VIB-Ghent University
• Introduction to High-resolution Spatial Transcriptomics for Agrigenomics
  Samik Bhattacharya, PhD, Resolve Biosciences

Please click here to register for the workshop in advance. Seating is limited.

Featured Presentations

• Filling Knowledge Gaps in Plant Single Cell Biology: Current and Future Perspectives
  Marc Libault, PhD, University of Nebraska-Lincoln
  Saturday, Jan. 14th at 2:45 pm PT in Town & Country Conference Center; Pacific D
• Spatially Resolved Transcriptomics in Plant and Animal Species
  Hilde Nelissen, PhD, VIB-Ghent University
  Friday, Jan. 13th at 2:10 pm PT in Town & Country Conference Center; Pacific C

Molecular Cartography Grant Program

The Resolve Biosciences Molecular Cartography Grant Program is designed to accelerate spatial transcriptomic research in specific areas by providing scientists with immediate, fully subsidized access to Molecular Cartography services. The inaugural Molecular Cartography Grant for Spatial Agrigenomics will be awarded to two researchers and will be based on study design, technical feasibility, and the potential to advance discovery in the field. The award will include the subcellular spatial transcriptomic analysis of up to eight samples using a fully customizable gene panel targeting RNA from up to 100 genes. For more information, please visit Molecular Cartography Grant Program – Spatial Agrigenomics.

Resolve’s pioneering Molecular Cartography technology provides the highest-resolution view of subcellular, single-molecule biology, allowing researchers around the world to gain new insights in neurology, oncology, developmental biology, and many other important biological research areas. The fully automated workflow features a proprietary, highly multiplexed, single-molecule fluorescence in situ hybridization technology. Unlike other approaches, the Molecular Cartography platform provides the required sensitivity, specificity, and workflow convenience to illuminate critical mechanisms, map interactions, and elucidate the cell’s complex transcriptional landscape without destroying the tissue section or cell culture sample. This innovative approach was designed for the multiplexing needs of most scientists in basic, translational, and clinical research. The underlying technology is modular and flexible, and is expected to incorporate the interrogation of DNA, protein, and metabolomic data layers in the future. The Molecular Cartography technology has already been cited in multiple manuscripts and peer-reviewed scientific publications.

---

Announcing the Winners of The Scientist’s Top 10 Innovations of 2022

Each year The Scientist highlights the latest and greatest tools, technologies, and techniques to hit the life science landscape. For more than a decade, we’ve been employing the assistance of expert panels of independent judges who weigh submissions of innovative products that are speeding work in laboratories and facilitating biological discovery.

This year’s crop of entries to The Scientist’s Top 10 Innovations contest included many with a clinical focus, and others that represent significant advances in sequencing, single-cell analysis, and more. The winners that emerged reflect the fact that the research enterprise continues to hum along as the world emerges from the worst that SARS-CoV-2 threw at us. “The pandemic forced the scientific community to pivot, but researchers did not give up on their ongoing projects,” says Managing Editor Jef Akst. “This year’s awardees are evidence of the exciting progress that’s been made in a wide range of fields.”

The winners of The Scientist’s Top 10 Innovations of 2022 contest are:

• 1. NeXT PersonalTM (Personalis): A personalized assay that detects, quantifies, and monitors circulating tumor DNA in order to spot molecular residual disease following surgical removal and track responses to therapy
• 2. CosMxTM Spatial Molecular Imager (NanoString Technologies): A product that visualizes and quantifies RNA and protein levels at the single-cell and even subcellular levels, and allows researchers to image multiple targets in one sample
• 3. UG100TM (Ultima Genomics): Technology that can sequence an entire human genome for US$100, and also boasts higher speed, better efficiency, and less waste than other sequencers, according to the company
• 4. ProteographTM Product Suite (Seer): A nanoparticle-based assay that allows unbiased sampling of all peptides in a biofluid sample, allowing researchers to track small molecular changes associated with disease and enabling the identification of novel and biologically relevant proteoforms
• 5. Live T Cell Assay (Nanolive): An application-specific digital assay that examines how T cells locate, bind, stress, and kill their targets, such as infected, foreign, or cancerous cells
• 6. MARS® Bar (Applied Cells, Inc.): A closed system that selects cells based on the presence of specific cell surface antigens and is not limited to use in a clean room or biosafety cabinet
• 7. Single Cellome™ System SS2000 (Yokogawa Electric Corporation): An automated subcellular sampling system that contains both a dual spinning-disk confocal microscope to visualize tissues and a sampling setup to collect either whole cells or intracellular components from a single cell
• 8. LightBench® Detect (Yourgene Health): A DNA processing tool that separates fragments by length for applications such as noninvasive prenatal testing, which involves analyzing fetal DNA collected from the mother’s blood
• 9. Molecular Cartography™ (Resolve Biosciences): A single-molecule fluorescence in situ hybridization technology that offers a three-dimensional view of gene expression within cells without damaging the tissue section or cell culture sample
• 10. OCELLOS 3.0 (TrakCel): A cloud-based software that tracks cell and gene therapies from extraction or manufacturing to the moment they’re administered to a patient, managing the chain of identity and chain of custody data that regulatory agencies require

Congratulations to this year’s winners. Be sure to visit the online feature where you can read more about the products that earned top spots and see comments from our expert judges.

---

Resolve Biosciences Appoints Chief Commercial Officer to Drive Worldwide Adoption of Molecular Cartography™ Workflow

Life science tools industry veteran Paul Steinberg will look to build on company’s recent success and allow more customers to gain insights from the clearest 3D view of subcellular spatial biology

MONHEIM AM RHEIN, Germany – October 25, 2022 – Resolve Biosciences, the pioneer in Molecular Cartography™ technology, today announced the appointment of Paul Steinberg as Chief Commercial Officer. The appointment follows the company’s recent $71 million Series B financing round, which was led by Patient Square Capital. Mr. Steinberg will be responsible for building on the company’s success, driving its commercial growth strategy, and leading its global sales, technical service, business development, and marketing functions.

“Over the last few months, we have secured a major round of funding and successfully installed our Molecular Cartography workflow at a growing number of leading European and North American laboratories, all despite unfavorable market conditions and the COVID-19 pandemic,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “After spending the past two decades growing core product lines for many of the most recognized life science tools companies, Paul is the perfect commercial leader to build our brand and to accelerate the worldwide adoption of our groundbreaking technology.”

Mr. Steinberg brings more than 20 years of experience leading commercial teams, corporate growth strategy, business development efforts, and global accounts in the life sciences tools industry. He has a long-standing history of successfully bringing disruptive single-cell and spatial technologies to market. Most recently, he served as the Chief Commercial Officer at LevitasBio, a provider of innovative cellular processing and characterization technologies. He also served as Vice President of Worldwide Sales at NanoString Technologies, where he led the go-to-market execution of the company’s spatial biology technology, as Senior Vice President of Commercial Operations at Fluidigm, where he sequentially introduced the market’s first single-cell and high-parameter protein imaging platforms, and in multiple divisional and corporate roles at Thermo Fisher Scientific. Mr. Steinberg holds a bachelor of science degree in biology and a master of science degree in analytical chemistry from the University of Miami.

“Resolve Biosciences has developed a game-changing technology platform that provides the clearest three-dimensional view of biology with full spatial context down to the subcellular, single-molecule level,” said Mr. Steinberg. “With so many demonstrated customer successes and a bold product development roadmap, our company is poised to lead this new era of single-cell spatial analysis. I am eager to join this talented team and to accelerate the process of delivering powerful Molecular Cartography results to labs around the world.”

Resolve’s pioneering Molecular Cartography technology provides the highest-resolution view of subcellular, single-molecule biology, allowing researchers around the world to gain new insights in neurology, oncology, developmental biology, and many other important biological research areas. The fully automated workflow features a proprietary, highly multiplexed, single-molecule fluorescence in situ hybridization technology. Unlike other approaches, the Molecular Cartography platform provides the required sensitivity, specificity, and workflow convenience to illuminate critical mechanisms, map interactions, and elucidate the cell’s complex transcriptional landscape without destroying the tissue section or cell culture sample. This innovative approach was designed for the multiplexing needs of most scientists in basic, translational, and clinical research. The underlying technology is modular and flexible, and is expected to incorporate the interrogation of DNA, protein, and metabolomic data layers in the future. The Molecular Cartography technology has already been cited in multiple manuscripts and peer-reviewed scientific publications.

American Society of Human Genetics 2022 Annual Meeting

Attendees will be able to experience Molecular Cartography data in virtual reality in booth #1843 at the ASHG 2022 Annual Meeting in Los Angeles on Oct. 25-29. Hear from leading researchers about how they are using the fully automated workflow to gain new insights in important biological research areas. For more information on the company’s activities, please visit https://resolvebiosciences.com/ASHG.

Breakfast Workshop Presentation

How do you Answer Biological Questions through Spatial Genomics

Wednesday, Oct. 26th at 7 – 8 am PT in Convention Center Room 304, South Building
Featured Presenters:

• Michael Snyder, PhD, Stanford Medicine
• Kelly Jin, PhD, Allen Institute for Brain Science

---

Resolve Biosciences Secures $71 Million Series B Financing to Accelerate Commercial Expansion to Meet Global Demand for Molecular Cartography™ Workflow

Funding led by Patient Square Capital follows successful launch of groundbreaking system that delivers highest-resolution view of subcellular, single-molecule, spatial biology

MONHEIM AM RHEIN, Germany – October 24, 2022 – Resolve Biosciences, the pioneer in Molecular Cartography™ technology, today announced it has secured a $71 million Series B financing. The latest round of funding was led by Patient Square Capital and included participation from EDBI, PS Capital, Alafi Capital, and NRW.BANK, as well as other existing investors. The company has now raised more than $100 million.

“Spatial biology is widely considered to be the most significant new field in life sciences,” said Laura Furmanski, PhD, Partner, and Head of Patient Square Insights at Patient Square Capital. “With its talented team and proprietary Molecular Cartography technology, Resolve is leading the new era of single-cell spatial analysis and opening the door to a wave of scientific findings that will redefine our understanding of disease and lead to new therapies and improved patient outcomes.”

Resolve’s groundbreaking Molecular Cartography technology provides the highest-resolution view of subcellular, single-molecule biology, allowing researchers around the world to gain new insights related to COVID-19 pathology as well as neurology, oncology, and developmental biology. Over the last few months, the workflow has been successfully installed at a growing number of leading European and North American laboratories, including VIB (Vlaams Instituut voor Biotechnologie) in Belgium, the Novo Nordisk Foundation Center at the University of Copenhagen, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), Stanford Medicine Department of Genetics, and the European Spatial Biology Center in Belgium. Resolve intends to build on its successful commercial launch and use the proceeds from the financing to rapidly scale operations and accelerate product development to meet growing demand worldwide.

“As we have seen through our service business and more recently our workflows installed in customer labs, our fully automated Molecular Cartography platform sets a new standard for subcellular spatial analysis technology,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “This Series B financing is another strong validation of our mission, our technology, and our team. We look forward to working with the Patient Square Capital team and empowering more visionary scientists with the tools to solve biology’s greatest challenges.”

Resolve’s Molecular Cartography workflow features a proprietary, highly multiplexed, single-molecule fluorescence in situ hybridization technology, which offers three-dimensional spatial context at subcellular resolution in a fully automated process. Unlike other approaches, the Molecular Cartography platform provides the required sensitivity, specificity, and workflow convenience to illuminate critical mechanisms, map interactions, and elucidate the cell’s complex transcriptional landscape without destroying the tissue section or cell culture sample. This innovative approach was designed for the multiplexing needs of most scientists in basic, translational, and clinical research. The underlying technology is modular and flexible, and is expected to incorporate the interrogation of DNA, protein, and metabolomic data layers in the future. The pioneering Molecular Cartography technology has already been cited in multiple manuscripts and peer-reviewed scientific publications.

In conjunction with the investment round, Resolve announced that Dr. Furmanski has joined the company’s Board of Directors.

---

Resolve Biosciences Sets New Standard for Single-Cell Spatial Analysis with Launch of Fully Automated Molecular Cartography™ Workflow

Pioneering scientists at VIB, the University of Copenhagen, DKFZ, and Stanford University are the first to deploy systems that deliver highest-resolution view of subcellular gene expression activity

MONHEIM AM RHEIN, Germany – June 7, 2022 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced the launch of its commercial Molecular Cartography workflow and the installation of the first systems at leading research institutions around the world. With this new advance, scientists are now able to apply the highest-resolution view of subcellular gene expression activity to gain new insights into critical biological mechanisms, interactions, and complexity.

Resolve Biosciences has successfully installed commercial systems in Europe and North America, including VIB (Vlaams Instituut voor Biotechnologie) in Belgium, the Novo Nordisk Foundation Center at the University of Copenhagen, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ), and the Stanford Medicine Department of Genetics. Previously, these customers accessed the power of the system through the company’s commercial Molecular Cartography service offering and early access program. These teams of scientists are now the first to apply the groundbreaking technology in their own laboratories to help resolve daunting challenges in neurology, oncology, infectious disease, developmental biology, and agricultural research.

Scientists at VIB have been evaluating Molecular Cartography technology for the past two years as part of a collaboration between Resolve’s early access program and VIB’s TechWatch program. One of the first proof-of-concept experiments, performed by teams at VIB-UGent Center for Inflammation Research, resulted in a spatial proteogenomic atlas of healthy and obese livers in mice. The two teams of scientists, led by Martin Guilliams, PhD, and Charlotte Scott, PhD, recently published findings that highlight evolutionarily conserved signaling pathways to maintain liver homeostasis and also provide a tool to identify biomarkers for immune and hepatic cells. The two Molecular Cartography workflows at VIB will now be used by a diverse set of scientific teams focused on advancing neuroscience, oncology, inflammation, and agricultural research.

“After testing and utilizing the Molecular Cartography technology for the past two years, we are confident that it will meet the enormous demand we have seen among VIB researchers who want to understand the spatial context of tissues at single-cell resolution,” said Dr. Guilliams. “We have applied Molecular Cartography to generate a spatial, single-cell atlas of the healthy human liver and discovered that a particular myeloid cell subset was always found in the direct vicinity of a specific stromal cell subset. This novel insight in the spatial architecture of the liver allowed us to discover a crucial growth factor exchange between these cells.”

“By applying Molecular Cartography to liver samples from patients and mice with fatty liver disease, we were able to identify a new subset of macrophages specifically localized in regions of lipid accumulation (steatosis),” said Dr. Scott. “This observation has now instructed a new research program to assess the functional and potential therapeutic relevance of these cells to better understand and ultimately decipher the mechanisms of disease pathology.”

The pioneering Molecular Cartography workflow features proprietary, highly multiplexed, single-molecule fluorescence in situ hybridization technology, which offers three-dimensional spatial context at subcellular resolution while maintaining sample integrity, all in a fully automated process. Unlike other approaches, the Molecular Cartography system provides the required sensitivity, specificity, and workflow convenience to elucidate the cell’s complex transcriptional landscape without destroying the tissue section or cell culture sample. This innovative approach was designed for the multiplexing needs of most scientists for basic, translational, and clinical research. The underlying technology is modular and flexible and is expected to incorporate the interrogation of DNA, protein, and metabolomic data layers in the future.

“The installation of our first commercial Molecular Cartography workflows is an incredible milestone for Resolve Biosciences. In just two years, we have had the pleasure of working with many world-renowned research institutions as part of our early access program and commercial service offering. These efforts have already resulted in multiple submitted manuscripts and peer-reviewed scientific publications,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “We are now focused on scaling our commercial operations to meet pent-up demand and empower more scientists with the tools needed to push the boundaries of science and gain new insights that are not possible with other approaches.”

Resolve Biosciences is the premier gold sponsor of the AGBT General Meeting, taking place this week in Orlando, Fla. The company is showcasing the latest scientific advances made possible by its Molecular Cartography workflow during the meeting. More than 20 leading biologists, virologists, and other scientists will be presenting posters and talks, sharing data on how they are using the innovative technology to resolve a wide variety of complex biological challenges. The Gold Sponsor Workshop and Lunch will feature presentations by Michael Snyder, PhD, Stanford Ascherman Professor, Chair of Genetics, and the Director of the Center of Genomics and Personalized Medicine at the Stanford University School of Medicine, and Nikolaus Rajewsky, PhD, Professor of Systems Biology at the Max-Delbrück-Center for Molecular Medicine, in the Bonnet Creek Ballroom Salon I-VI at 12 pm ET on Tuesday, June 7, 2022.

---

Resolve Biosciences to Showcase Agrigenomic Applications for Molecular Cartography™ Platform at Advances in Genome Biology and Technology Agriculture Meeting

Six leading agricultural scientists will share new insights gained from the highest-resolution view of subcellular spatial biology

SAN DIEGO and MONHEIM AM RHEIN, Germany – April 4, 2022 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced a lineup of customer presentations at the inaugural Advances in Genome Biology and Technology (AGBT) Agriculture Meeting in San Diego on April 4-6, 2022. Meeting attendees will be able to learn more about the technology in booth #304 and hear six leading international scientists present data on how they are applying the power of the Molecular Cartography spatial transcriptomics technology to identify pathways that disrupt and advance agricultural genomics research.

“Resolve Biosciences’ pioneering Molecular Cartography technology is enabling the global scientific community to analyze highly complex formalin-fixed paraffin-embedded plant samples at subcellular resolution and gain valuable insights that are not possible with other single-cell or spatial biology platforms,” said Jason T. Gammack, co-founder and CEO of Resolve Biosciences. “We are proud to be working with all of these visionary scientists who are pushing the boundaries of agricultural genomics to help improve and increase sustainable food production.”

Featured Presentations

• Validation of maize ear and root single-cell data by spatial transcriptomics using Molecular Cartography
  David Jackson, PhD, Cold Spring Harbor Laboratory
• Single-cell transcript mapping in a monocot species using Molecular Cartography
  Philip Benfey, PhD, Duke University
• Mapping cellular divergence in cereals using single-cell and single-nuclei RNA-sequencing and Molecular Cartography
  Kenneth Birnbaum, PhD, New York University
• Combining single-cell transcriptomics and Molecular Cartography for fast molecular characterization of novel model species
  Jim Renema, Ghent University
• Unleashing the power of single-cell technologies: combining single-nuclei RNA-seq and Molecular Cartography in soybean
  Marc Libault, PhD, University of Nebraska-Lincoln
• Identifying meristem-type specific regulatory circuits in complex inflorescences of barley using transcriptomics at single-cell resolution
  Edgar Demesa-Arevalo, PhD, Heinrich Heine University

Resolve’s Molecular Cartography platform is the only spatial biology platform suitable for highly complex plant samples. The platform currently delivers the highest-resolution view of transcriptomic activity and provides the ability to interrogate hundreds of genes in a single run. Unlike other current approaches, the Resolve platform provides the required sensitivity, specificity, and workflow convenience to elucidate a cell’s complex transcriptional landscape. The technology produces deep contextual data sets that illuminate molecular interactions at subcellular resolution while preserving the sample tissue. The intuitive bioinformatics workflow can be easily integrated with other widely used spatial biology analysis tools.

Resolve Biosciences is also the premier gold sponsor of the upcoming AGBT General Meeting, which has been rescheduled for June 6-9, 2022. The company will unveil its commercial Molecular Cartography platform during the meeting and more than 20 leading biologists, virologists, and other scientists will be presenting data on how they are using the innovative technology to resolve a wide variety of complex biological challenges.

---

Resolve Biosciences Joins EMBL’s Corporate Partnership Programme

Single-cell spatial analysis pioneer continues to invest in initiatives that train and support the next generation of molecular life scientists

MONHEIM AM RHEIN, Germany – Dec. 9, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced a corporate partnership with the European Molecular Biology Laboratory (EMBL). As part of the EMBL’s Corporate Partnership Programme (CPP), Resolve Biosciences will support molecular life science training. The financial support will enable young researchers to attend scientific conferences and courses, where they can present exciting new discoveries, and interact with scientific leaders from around the globe.

EMBL is the leading life science laboratory in Europe with more than 80 independent research groups covering the spectrum of molecular biology. The CPP was founded in 2009 to support collaboration and training for the next generation of molecular life scientists. The programme aims to connect industry leaders with leading molecular life scientists and biomedical researchers.

“EMBL warmly welcomes Resolve Biosciences to our Corporate Partnership Programme, and we look forward to working together to offer more inclusive access to our world-leading advanced scientific training for scientists who may otherwise be unable to participate,” said Edith Heard, EMBL Director General. “EMBL was established nearly 50 years ago to promote and enhance the life sciences across Europe, and the CPP plays an important role by helping support the development and promotion of innovative and groundbreaking scientific events in Europe.”

“EMBL is a world-renowned center for excellence known for its ongoing commitment to identifying, supporting, and training the next generation of scientists. The team at Resolve Biosciences is proud to continue this legacy and be part of EMBL’s Corporate Partnership Programme,” said Jason T. Gammack, Co-founder and CEO of Resolve Biosciences. “Spatial biology is the new frontier in biomedical research, and we look forward to enabling more researchers to apply the power of our groundbreaking Molecular Cartography technology to resolve the most daunting challenges in biology.”

For more information on EMBL’s Corporate Partnership Programme, please visit
https://www.embl.org/about/info/support/embl-corporate-partnership-programme.

---

Resolve Biosciences Appoints Oliver Dick as Chief Operating Officer

Renowned global operations and manufacturing executive will drive excellence and scale business to meet growing demand for the company’s Molecular Cartography™ system

MONHEIM AM RHEIN, Germany – Dec. 1, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced the appointment of Oliver Dick, PhD, as Chief Operating Officer. In this role, Dick will report to Co-founder and CEO Jason T. Gammack. He will be responsible for overseeing and scaling the company’s strategic planning, manufacturing, supply chain, quality control, information technology, and logistics functions to meet growing worldwide demand for the company’s groundbreaking Molecular Cartography platform for high-resolution spatial biology.

“As a startup company with a transformative spatial transcriptomic technology, one of our most important areas of focus is scaling the business as quickly and robustly as possible to take advantage of the tremendous opportunity we see in the market today. Oliver’s operational experience will help us achieve that goal much faster,” said Gammack. “I have worked closely with Oliver in the past and have been inspired by his commitment to operational excellence. His expertise and leadership will be instrumental as we position the company and our proprietary Molecular Cartography platform for long-term success.”

Dick is an experienced leader who has spent more than 30 years in the life sciences, pharmaceutical, and diagnostics industries. He recently served as Chief Operating Officer at Miltenyi Biotec, where he was responsible for developing and deploying the company’s growth strategy. Prior to that, Dick spent more than 12 years at QIAGEN where he was Vice President of Global Manufacturing for Life Sciences and Diagnostics. He was responsible for all engineering, procurement, logistics, manufacturing, and quality control functions at QIAGEN’s production facilities around the world. In this capacity, he also oversaw the integration of many successful acquisitions and continuously optimized processes to improve technology programs and reduce overall costs of goods. Prior to joining QIAGEN, Dick held management positions at Rentschler Biotechnologies, Pharmaplan, and the Pall Corporation. Dick received his PhD in chemical and bioprocess engineering from TU Dortmund University.

“Resolve Biosciences is poised to push the boundaries of spatial analysis and lead this next era in modern molecular biology,” said Dick. “Together, we will implement robust operational processes to help scale the business, drive efficiencies, and pursue excellence across the entire organization. We will make sure the Resolve Biosciences brand will be known for its high-quality precision engineering, reliability, and commitment to a world-class customer experience.”

Oliver Dick’s appointment completes Resolve’s leadership team. Over the past year, the company announced the appointment of Chris Barbazette as Chief Commercial Officer, Frank Zhong as Chief Technology Officer, and Erik Wiberg as Chief Financial Officer. Scientists interested in learning more about the innovative Molecular Cartography services can contact the Resolve team.

---

Announcing the Winners of The Scientist’s Top 10 Innovations of 2021

Each year The Scientist seeks to highlight the latest and greatest tools, technologies, and techniques to hit the life science landscape. For more than a decade, we’ve been employing the assistance of expert panels of independent judges who weigh submissions of innovative products speeding work in laboratories and facilitating biological discovery. This year’s crop of entries to The Scientist’s Top 10 Innovations contest reflected the fact that the scientific community, like the whole of society, has been adjusting to a new reality marked by the second year of an extremely challenging and taxing global pandemic. At the same time, work in other areas of the life sciences has preserved. “In a way, it’s heartening that scientific advances have continued to occur in spaces outside of the crucial coronavirus focus,” says Editor-in-Chief Bob Grant. “It suggests that the global biomedical apparatus is robust enough to address a pressing and pointed concern while not losing ground in fields not directly related to that crisis.”

The winners of The Scientist’s Top 10 Innovations of 2021 contest are:

1. nVue^TM System (Inscopix) – This “miniaturized microscope” enables dual color imaging of two distinct brain signals in freely-behaving animals, such as two neuronal populations or neural activity in conjunction with brain blood flow.
2. PhysioMimix^TM Multi-Organ System (CN Bio) – The microfluidic platform allows scientists to connect individual organ-on-a-chip models for disease research and drug development.
3. MERSCOPE^TM (Vizgen) – This single-cell spatial genomics instrument, the only one currently available for purchase, detects RNA transcripts from hundreds of genes across intact tissue and returns imaging and expression data at subcellular resolution.
4. Brain-Chip (Emulate) – This organ-on-a-chip model consists of two channels embedded in flexible rubber polymer—one channel represents blood vessel walls and the other represents the brain—and midway along the chip, the two channels come into contact, allowing scientists to study the blood-brain barrier.
5. Gemini and Mark I (Q Bio) – The Mark I prototype scans the entire body using magnetic resonance imaging (MRI), and the imaging results are uploaded to the Gemini platform, along with medical records, genetics data, and traditionally acquired tests of blood, urine, saliva, and vital signs, to create a “digital twin” of the patient.
6. Chromium X (10X Genomics) – Loading cells, reagents, and a partitioning oil into a microfluidic chip, researchers can use this benchtop instrument to create droplets, or Gel Bead-In-Emulsions (GEMs), that each contain a single cell, a single barcoded Gel Bead, and a reagent, and are ready to be sequenced and used in assays offered by 10x Genomics.
7. SARS-CoV-2 Neutralization Assay Development Kits (The Native Antigen Company) – This coronavirus neutralization assay uses synthetic versions of the SARS-CoV-2 spike protein’s receptor binding domain and its target, the mammalian ACE-2 receptor, to quantify a serum sample’s level of antibodies that bind, and therefore neutralize, the virus, as evidenced by a color change.
8. Tapestri Single-cell Multi-omics Solution (Mission Bio) – This process for single-cell analysis allows users to consider DNA sequence and proteomic information simultaneously, and therefore correlated at the single-cell level.
9. CRISPR-SNP-Chip (Cardea Bio) – Equipped with a CRISPR-Cas system tethered to a graphene transistor, this device is the first of its kind that can detect single base differences in DNA without generating millions of copies of the DNA first.
10. Molecular Cartography^TM Single-Cell Spatial Analysis Service (Resolve Biosciences) – This mail-in service offers fluorescence in situ hybridization (FISH) to create high-resolution images of individual RNA transcripts inside intact tissues—down to the subcellular level.

Congratulations to this year’s winners. Be sure to visit https://www.the-scientist.com/features/2021-top-10-innovations-69438 where you can read more about the products that earned top spots and see comments from our expert judges.

---

Resolve Biosciences Strengthens Leadership Team with Appointment of Frank Zhong as Chief Technology Officer

Former product innovator at BGI, Illumina, and Pacific Biosciences will spearhead technological development of breakthrough Molecular Cartography™ system

MONHEIM AM RHEIN, Germany – Nov. 2, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced the appointment of Frank Zhong, PhD, as Chief Technology Officer. In this role, Zhong will report to Co-founder and CEO Jason T. Gammack and be responsible for overseeing all product development and advanced research activities that drive the company’s groundbreaking Molecular Cartography platform for high-resolution spatial biology.

“Over the past year, Resolve Biosciences has made tremendous strides as a business. We have built a world-class team, strengthened our footprint on two continents, and launched our commercial Molecular Cartography service offering,” said Gammack. “I am pleased to welcome Frank to our team, where his perspective and expertise in implementing industry-leading technologies will be invaluable as we look to push the boundaries of our Molecular Cartography platform and enable more customers to gain a deeper understanding of biological mechanisms, interactions, and complexity.”

Zhong brings to Resolve more than 20 years of experience conducting life science research and developing innovative genomic analysis tools for premier biotechnology companies. He recently served in senior leadership roles at the BGI Group, including CEO of EGI Inc., CTO of BGI Research USA, and Vice President of Advanced Research at Complete Genomics, where he assembled a global development team for the next-generation sequencing and automation products, including an integrated sample-to-result benchtop platform. Prior to working at BGI, Zhong was Associate Director of Technology Development at Illumina Inc., where he focused on advanced technology and systems, including the company’s first integrated semiconductor sensor-based platform, iSeq. Before that, he served in a series of system development roles at Pacific Biosciences, Inc., where he worked on optical systems and invented silicon photonics technology for the company’s single-molecule, real-time sequencing platforms. Zhong received his PhD in applied physics and master of science degree in electrical engineering from the University of Michigan. He also studied physics at Peking University in China before he moved to the USA.

“Spatial biology is an exciting new frontier in biomedical research that pairs innovative approaches with adjacent technologies and builds on many advances from DNA sequencing and single-cell genomics,” said Zhong. “Resolve’s Molecular Cartography platform uniquely provides researchers with the highest-resolution view of subcellular transcriptomic activity and the required sensitivity, specificity, and workflow convenience to answer complex biological questions that we’ve never been able to ask. I’m proud to be a part of this visionary team and look forward to expanding the company’s foundational research and development efforts to create new tools that will transform our understanding of complex biological systems.”

Frank Zhong is the latest addition to Resolve’s executive team. The company also recently announced the appointment of Chris Barbazette as Chief Commercial Officer and Erik Wiberg as Chief Financial Officer. Scientists interested in learning more about the innovative Molecular Cartography services can contact the Resolve team.

---

Resolve Biosciences Appoints Erik Wiberg as Chief Financial Officer

Experienced senior leader brings proven track record of developing financial strategies that drive operational excellence and accelerate global expansion

MONHEIM AM RHEIN, Germany – Sept. 13, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced the appointment of Erik Wiberg as Chief Financial Officer. In this role, Mr. Wiberg will report to Co-founder and CEO Jason T. Gammack and be responsible for the company’s finance, legal, human resources, and administrative functions.

“Resolve Biosciences is building a world-class team featuring top entrepreneurial talent from Silicon Valley with leading genomics and precision engineering experts in Germany,” said Mr. Gammack. “Erik is an extraordinary leader with a strong track record of developing and implementing comprehensive financial strategies for early-stage growth companies. His broad industry experience and passion for cutting-edge science make him a perfect fit for Resolve as we look to accelerate growth, drive operational excellence, and position the company for long-term commercial success.”

Mr. Wiberg brings more than 30 years of experience, including CFO roles at public and private firms in the medical device and biotechnology industries. Prior to joining Resolve, he served as CFO at REVA Medical, a leading provider of bioresorbable polymer technologies for vascular applications. He also held the CFO and Vice President of Administration position at Gyros Protein Technologies AB, as well as senior finance leadership positions at Thermo Fisher Scientific, AlliedSignal, and the Chamberlain Group. Mr. Wiberg holds a bachelor of science degree in mechanical engineering from the University of California, San Diego, as well as a master’s degree in machine vision and optics and an MBA from the University of California, Los Angeles.

“Resolve offered a unique, life-changing opportunity to join an international company that is poised to lead the next generation in molecular analysis,” said Mr. Wiberg. “I’m looking forward to relocating to Germany, working with this exceptional team of professionals, and enabling more scientists to apply the power of Molecular Cartography to resolve some of the most complex challenges in biology.”

Scientists interested in learning more about the innovative Molecular Cartography services can contact the Resolve team.

---

Resolve Biosciences and ZEISS Announce Co-Development Collaboration to Enhance Highest-Resolution View of Subcellular Spatial Biology

Molecular Cartography™ platform features leading microscopy and 3D imaging capabilities

MONHEIM AM RHEIN and JENA, Germany – Aug. 3, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, and ZEISS today announced a co-development collaboration to advance spatial biology applications. The companies are working together to optimize advanced microscopy and 3D imaging solutions for subcellular spatial analysis. ZEISS microscopy technology is part of Resolve’s current Molecular Cartography service offering and will be incorporated into the commercial spatial transcriptomics system scheduled to launch later this year.

Resolve’s Molecular Cartography platform enables scientists to resolve the most complex biological challenges in areas such as oncology, neuroscience and infectious disease. Through this collaboration, ZEISS and Resolve Biosciences will combine leading optical technologies and engineering expertise with multi-analyte and highly multiplexed spatial analysis to illuminate molecular interactions at subcellular resolution while preserving the sample tissue. The companies will work together to enhance the Molecular Cartography workflow through the development of novel optical systems and computational approaches.

“This collaboration with Resolve Biosciences will enable scientists to achieve the highest-quality results in an integrated workflow with optimized throughput,” said Michael Albiez, Head of ZEISS Research Microscopy Solutions. “As the next frontier of biological research, spatial analysis presents the perfect opportunity to apply our advanced microscopy solutions for the clearest view of biological systems. We are committed to working with the Resolve team to allow more researchers to gain new insights in subcellular spatial biology.”

Resolve’s Molecular Cartography platform has been under development since 2016 and is currently available through a commercial service offering to researchers in Europe and North America. Unlike other current approaches, the Resolve platform provides the required sensitivity, specificity and workflow convenience to elucidate a cell’s complex transcriptional landscape. The technology produces deep contextual data sets that illuminate molecular interactions at subcellular resolution while preserving the sample tissue. Resolve’s Molecular Cartography platform currently delivers the highest-resolution view of transcriptomic activity and provides the ability to interrogate hundreds of genes in a single run. Future iterations of the technology will add DNA, protein and metabolomic data layers.

“Through this alliance, we now have access to key resources to scale our services business and are well on our way to providing our customers with a complete commercial system that features the latest advances in German precision engineering,” said Jason T. Gammack, Co-founder and CEO of Resolve Biosciences.

ZEISS Research Microscopy Solutions
ZEISS Research Microscopy Solutions is the world’s only one-stop manufacturer of light, electron, X-ray and ion microscope systems and offers solutions for correlative microscopy. The portfolio comprises of products and services for life sciences, materials and industrial research, as well as education and clinical practice. The unit is headquartered in Jena. Additional production and development sites are located in Oberkochen and Munich, as well as in Cambourne (UK) and Dublin (USA). ZEISS Research Microscopy Solutions is part of the Industrial Quality & Research segment.

---

Resolve Biosciences Launches Commercial Molecular Cartography™ Services to Provide Scientists with Highest-Resolution View of Subcellular Gene Expression

Company expands global footprint with opening of US facility and appoints industry veteran Chris Barbazette to lead rapidly growing commercial organization

MONHEIM AM RHEIN, Germany, and SAN JOSE, Calif. – June 2, 2021 – Resolve Biosciences today announced the commercial launch of its groundbreaking Molecular Cartography™ service offering to provide scientists with the highest-resolution view of subcellular gene expression. Through this new service offering, customers in North America and Europe will be able to submit their samples of interest for analysis and receive data back from Resolve’s technical team. To help meet the significant global demand for its next-generation spatial analysis technology, Resolve is expanding capabilities in Europe and has opened a North American facility in San Jose, Calif. In addition, Resolve has appointed Chris Barbazette as Chief Commercial Officer to lead the company’s growing sales and marketing operations.

Under development since 2016, Resolve’s Molecular Cartography platform consists of proprietary, highly multiplexed, single-molecule detection technology to measure transcriptomic activity with full spatial context at subcellular resolution. During the past year, the technology has demonstrated groundbreaking capabilities in several high-profile early access collaborations to better understand human brain development, cell type evolution, and how the SARS-CoV-2 infection affects neighboring cells over time. Unlike other spatial analysis techniques, the Resolve platform provides the required sensitivity and specificity to elucidate a cell’s complex transcriptional landscape. The technology generates deep contextual data sets that illuminate molecular interactions while preserving sample tissue for future analysis.

“We believe the power of spatial biology lies in enabling a deeper understanding of biological mechanisms, interactions, and complexity,” said Jason T. Gammack, Co-founder and CEO of Resolve Biosciences. “After the resounding success of our early access program, we are now delivering our innovative Molecular Cartography services to leading institutions throughout the US and Europe.”

Global Footprint and Commercial Operations Expansion
To help support the global demand for its Molecular Cartography services, Resolve is rapidly expanding its team and opening a new state-of-the-art office and laboratory in San Jose. The new facility will augment the company’s German headquarters and provide regional support to the company’s growing customer base in North America. Chris Barbazette, who brings a proven track record of introducing disruptive technologies and directing successful global commercial organizations, will oversee the new facility and commercial operations around the world.

Mr. Barbazette previously held senior commercial positions at GenapSys, Agendia, and Affymetrix. As Senior Vice President of Global Commercial Operations at Affymetrix, he was responsible for building a robust worldwide distribution network that brought the latest genotyping and gene expression solutions to customers in more than 40 countries.

“Resolve Biosciences has the right team and technology platform to lead the next generation of genomic analysis. Molecular Cartography provides high-resolution spatial context and adds a valuable new dimension to scientific research that enables a better understanding of biological mechanisms and functions,” said Mr. Barbazette. “I’m looking forward to supporting our growing customer base and empowering them with tools to provide insights that will transform life sciences research and, eventually, clinical diagnostics.”

Scientists interested in learning more about the innovative Molecular Cartography services can contact the Resolve team.

---

Resolve Biosciences Announces Initial Results from Early Access Collaborations with Scientists Leading the Next Generation of Subcellular Spatial Analysis

The power and resolution of the Molecular Cartography™ platform is illuminating important cellular interactions in COVID-19 pathology, neurology, and developmental biology research

MONHEIM AM RHEIN, Germany – Feb. 22, 2021 – Resolve Biosciences, the pioneer in Molecular Cartography™, today announced initial results from several prominent early access collaborations with leading laboratories across Europe. Teams of scientists are currently using the groundbreaking subcellular spatial analysis technology to help resolve daunting challenges in COVID-19 pathology, neurology, and developmental biology research.

Under development since 2016, Resolve’s Molecular Cartography platform features the company’s proprietary, highly multiplexed, single-molecule detection technology to provide the highest-resolution view of subcellular transcriptomic activity. Unlike other spatial analysis techniques, the Resolve platform provides the required sensitivity, specificity, and workflow convenience to elucidate the cell’s complex transcriptional landscape. The technology generates deep contextual data sets that illuminate molecular interactions at subcellular resolution while preserving the sample tissue for future analysis.

The Resolve Molecular Cartography platform has been available through an oversubscribed early access program during the past year. Initial findings from several of the high-profile projects include:

• SARS-CoV-2 Infection and Inflammatory Response — Medical University of Graz, Austria
  The laboratory led by Kurt Zatloukal, MD, Professor of Pathology and Head of the Diagnostic and Research Center for Molecular Biomedicine, is using the Molecular Cartography platform to study the molecular pathology behind SARS-CoV-2 infection and the subsequent inflammatory response on the mRNA level that leads to severe disease. The Resolve technology offers the ability to explore the distribution of infected cells, their morphology, and molecular activity at the same time. The team analyzed different cell culture systems to compare the transcriptomic activity of more than 80 genes in infected cells and non-infected cells, explore how cells react to changes in gene expression upon viral infection, analyze the exact position of transcripts within cells, and investigate how the antiviral host response can trigger tissue damage. The initial results have provided a better understanding of subcellular gene regulation and how the infection affects neighboring cells over time.
• Human Brain Development — MRC Laboratory of Molecular Biology, Cambridge, UK
  Madeline A. Lancaster, PhD, Group Leader in the Cell Biology Division, and her team are applying the power of Molecular Cartography to brain organoids to unravel the spatial logic of neural tissue development. Since the technology reliably captures spatiotemporal gene expression, researchers can study key aspects of human brain function and development in vitro. The team used the technology to detect and quantify expression with ultra-high sensitivity, showing 100 gene transcripts simultaneously at subcellular resolution. The initial results suggest that the spatial distribution of mRNA molecules for outer radial glia (oRG) cell markers is not confined to the outer subventricular zone but rather is spread throughout the whole proliferative ventricular zone. This observation highlights the necessity to look for more specific oRG markers to be applied in the context of brain organoids.
• Retina Gene Expression and Cell Type Evolution — University College London, UK
  Ryan MacDonald, PhD, Biotechnology and Biological Sciences Research Council David Phillips Fellow and Lecturer at the Institute of Ophthalmology, and his colleagues are using Molecular Cartography technology to better understand how a healthy retina develops and changes with advancing age. Scientists were able to visualize the spatial expression of 48 genes simultaneously in the same zebrafish sample to observe the development of different cell types using specific marker genes in the retina. Then by visualizing gene expression changes over the entire lifespan, specifically within the support cells called glia, they were able to identify candidate genes that are dysregulated in the aging retina and potentially underlie progressive neuronal degeneration and vision loss.

“Thanks to its exquisite resolution, the technology from Resolve Biosciences allows us to detect specific gene expression patterns in SARS-CoV-2 that we could not see with existing RNA sequencing or single-cell RNA-seq technologies,” said Prof. Zatloukal. “Since the Resolve workflow provides spatial information at subcellular resolution and still preserves the tissue integrity, we see clear clinical opportunities with this approach moving forward.”

“Over the past year, Resolve Biosciences has had the privilege of working with many of the true visionaries of single-cell and spatial biology,” said Jason T. Gammack, Co-founder and CEO of Resolve Biosciences. “We are grateful for their engagement and feedback, and proud that they were able to gain new insights that were not possible with alternative approaches. We look forward to empowering more scientists around the world with this same ability to rapidly advance the understanding of complex biology with our novel Molecular Cartography platform.”

Resolve Biosciences is now expanding its early access program globally. Scientists interested in learning more about how to access and apply the power of its innovative Molecular Cartography technology can contact the company. 

---

Resolve Biosciences Launches New Era in Single-Cell Spatial Analysis

Company announces $24 million Series A financing and appoints Jason T. Gammack as CEO to accelerate development and commercialization of Molecular Cartography™ platform

MONHEIM AM RHEIN, Germany – Dec. 10, 2020 – Resolve Biosciences, the pioneer in Molecular Cartography™, announced the completion of a $24 million Series A financing round and the appointment of Co-founder Jason T. Gammack as Chief Executive Officer.

The company’s Molecular Cartography platform is a groundbreaking multi-analyte and highly multiplex spatial analysis technology that enables scientists to resolve the most daunting biological challenges in areas such as oncology, neuroscience, and infectious disease. It produces deep contextual data sets that illuminate molecular interactions at subcellular resolution, while preserving the sample tissue. The initial applications of Resolve’s Molecular Cartography platform deliver the highest-resolution view of transcriptomic activity and provide the ability to interrogate hundreds of genes in a single run. Future solutions will add DNA, protein, and metabolomic data layers. Unlike current approaches, Resolve’s technology provides the required sensitivity, specificity, and workflow convenience to elucidate the cell’s complex transcriptional landscape.

Series A Financing

The Series A financing round was led by PS Capital Management and MasterMind Advisory Services and included participation from Alafi Capital, John Shoffner, and High Tech Gründerfonds. The company will use the proceeds to accelerate product development and drive industry adoption of its Molecular Cartography technology.

“Molecular Cartography creates a new dimension of spatial analysis, which will soon expand the frontiers of modern molecular biology. Our innovative solution enables valuable scientific insights that far exceed the reach of legacy spatial biology technologies,” said Peer M. Schatz, Chairman and Co-founder of Resolve Biosciences. “Jason is an accomplished leader in the field of advanced genomics, and I’m looking forward to working with him again to help Resolve Biosciences transform the future of life sciences research and clinical diagnostics.”

CEO Appointment

Jason T. Gammack brings more than 25 years of life sciences industry experience and has developed successful product and customer engagement strategies for some of its preeminent biotechnology brands. He recently served as Chief Commercial Officer at Inscripta, where he oversaw sales, marketing, business development, and customer support for the company’s CRISPR-enabled Onyx™ Digital Genome Engineering platform. Before that, he was Vice President of the Life Science Business at QIAGEN, where he led the life science portfolio and go-to-market strategy. Earlier in his career, Gammack developed commercialization growth strategies at Ingenuity Systems, a leading bioinformatics company acquired by QIAGEN in 2013. He has also held senior leadership roles at Sigma-Aldrich, Invitrogen/Life Technologies, Affymetrix, and Promega Corporation.

“Resolve Biosciences’ pioneering Molecular Cartography platform powers novel insights by enabling scientists to gain the highest-resolution view of subcellular gene expression activity,” said Gammack. “Together with our talented team of scientists and investors, we are poised to lead the next generation of single-cell analysis and support scientists around the world as they apply the latest advances of our Molecular Cartography technology platform to solve the most complex biological questions.”